Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

Qt's solid architecture, easy-to-use APIs, and many tools have made it a popular choice for building multiplatform projects.

User engagement has recently received significant attention in understanding the decay and expansion of communities in many online social networking platforms. Many user engagement studies have been ...

Vertex Pharmaceuticals shares fell 14% in post-market trading Monday after the company said it will not advance its ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...